可溶性ST2与慢性心力衰竭

Soluble ST2 and chronic heart failure

慢性心力衰竭(CHF)是各种心脏疾病的终末阶段,尽管诊疗手段日益进步,在中国CHF仍是严峻的健康问题。CHF预后较差,严重心衰患者1年死亡率高达50%。寻找特异、灵敏的生物标志物对CHF的诊断、治疗和预测不良预后有重要的临床意义。可溶性ST2由于不受年龄、体质量等影响而成为了研究的热点,多项研究表明s ST2对CHF的诊断、预后及危险分层中都具有重要的临床意义。

Chronic heart failure is the end stage of various heart diseases. Despite improvements in diagnosis and therapy, chronic heart failure is a major medical problem in China. The prognosis of chronic heart failure is poor, and the mortality of severe heart failure is as high as 50%. It is of great clinical significance to find specific and sensitive biomarkers for the diagnosis, treatment and prognosis of chronic heart failure. Soluble ST2 has become a hotspot because it is not influenced by factors such as age and weight. Many studies have shown that sST2 is of great clinical significance for diagnosis, prognosis and risk stratification in chronic heart failure.